EU Okays Bevacizumab in Ovarian Cancer, Regorafenib in GISTEU Okays Bevacizumab in Ovarian Cancer, Regorafenib in GIST
Another use in a ovarian cancer is recommended for approval in Europe, as is use of regorafenib for gastrointestinal stromal tumors (GIST). International Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Gastroenterology | Hematology | Ovarian Cancer | Ovaries